Loading…
Loading…
LMRI (Lumexa Imaging Holdings, Inc. Common Stock) is a recent IPO.
It began trading on December 11, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
LMRI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LMRI and 80,000+ other tickers.
See exactly how LMRI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LMRI and 80,000+ other tickers.
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RALEIGH, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the formation of a strategic joint venture with Hospital for Special Surgery (HSS), world leader in musculoskeletal health.
Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript